Tier 4 — mechanistic

Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for Previously Treated Glioma With Residual Disease

Mayo Clinic study team
ClinicalTrials.gov trial registry record 2025

Bibliography

Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Sponsor: Mayo Clinic.
Competing interests
Not reported in the registry record.

Study snapshot

DesignEarly Phase 1 interventional study testing sequential senolytic/chemotherapy combinations.
ModelAdults with previously treated glioma and residual disease.
SamplePlanned enrollment: 10 participants.
InterventionSequential treatments or combinations can include dasatinib, quercetin, fisetin and temozolomide. The public 2026 review does not provide a stand-alone fisetin dose.
DurationEarly-phase treatment and safety evaluation through the registered study period.
EndpointsSafety and tolerability; Dose-limiting toxicity; Preliminary therapeutic activity; Imaging and disease-control measures

What the study showed, in plain terms

This Mayo Clinic early-phase study includes fisetin inside sequential or combination regimens with dasatinib, quercetin and temozolomide for previously treated glioma.

Because fisetin is not being evaluated as a simple stand-alone intervention and the sample is only about ten participants, the study is primarily a safety/feasibility signal. Any future tumor outcome cannot automatically be assigned to fisetin.

Key findings

  • Planned sample size is 10.
  • Fisetin is one component of sequential/combination senolytic and chemotherapy regimens.
  • No efficacy results are available.

What this study can and cannot tell us

  • Very small early-phase study.
  • Combination design prevents clean fisetin-specific attribution.
  • Cancer-treatment setting and concomitant therapies make supplement extrapolation inappropriate.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology